SLC5A5 and breast carcinoma: To extend the use of NIS-mediated radioiodine therapy to other types of cancer, we successfully transferred and expressed the sodium-iodide symporter (NIS) gene in prostate, colon, and breast cancer cells, both in vivo and in vitro, by using adenoviral vectors.